About Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase
Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase (ST8SIA1) is a protein
from Homo sapiens identified by UniProt accession
Q92185, 356 residues long.
MolForge cross-references it against 0 known binders and
94 disease associations.
Target properties
| Protein name | Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase |
|---|
| UniProt accession | Q92185 |
|---|
| Gene | ST8SIA1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 356 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (94)
Diseases linked to this target (Open Targets).
- body height · score 0.37
- smoking status measurement · score 0.29
- age at onset · score 0.28
- refractive error · score 0.28
- Myopia · score 0.28
- Abnormality of refraction · score 0.28
- platelet count · score 0.14
- platelet component distribution width · score 0.13
- platelet crit · score 0.13
- triple-negative breast cancer · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q92185-F1 | alphafold | PREDICTED | 88.52 | — |
Amino-acid sequence (356 residues)
MSPCGRARRQ TSRGAMAVLA WKFPRTRLPM GASALCVVVL CWLYIFPVYR LPNEKEIVQG VLQQGTAWRR NQTAARAFRK QMEDCCDPAH LFAMTKMNSP MGKSMWYDGE FLYSFTIDNS TYSLFPQATP FQLPLKKCAV VGNGGILKKS GCGRQIDEAN FVMRCNLPPL SSEYTKDVGS KSQLVTANPS IIRQRFQNLL WSRKTFVDNM KIYNHSYIYM PAFSMKTGTE PSLRVYYTLS DVGANQTVLF ANPNFLRSIG KFWKSRGIHA KRLSTGLFLV SAALGLCEEV AIYGFWPFSV NMHEQPISHH YYDNVLPFSG FHAMPEEFLQ LWYLHKIGAL RMQLDPCEDT SLQPTS
Explore Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets